Fernando Lecanda Selected Research

Biomarkers (Surrogate Marker)

11/2020	Sarcoma treatment in the era of molecular medicine.
10/2019	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
11/2018	Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma.
4/2017	The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models.
10/2015	Bone metastases in lung cancer. Potential novel approaches to therapy.
1/2013	miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis.
1/2012	Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fernando Lecanda Research Topics

Disease

36	Neoplasms (Cancer) 01/2022 - 08/2004
20	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2008
18	Osteosarcoma (Osteogenic Sarcoma) 10/2020 - 01/2008
11	Lung Neoplasms (Lung Cancer) 01/2022 - 10/2007
7	Carcinogenesis 01/2020 - 08/2004
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 12/2014
3	Sarcoma (Soft Tissue Sarcoma) 11/2020 - 01/2019
3	Inflammation (Inflammations) 12/2014 - 08/2004
2	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2017
2	Carcinoma (Carcinomatosis) 04/2017 - 08/2004
2	Adenocarcinoma of Lung 12/2014 - 07/2012
1	Bile Duct Neoplasms (Bile Duct Cancer) 01/2021
1	Osteoradionecrosis 01/2021
1	Cholangiocarcinoma 01/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021
1	Necrosis 01/2021
1	Starvation 01/2020
1	Circulating Neoplastic Cells 11/2018
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015
1	Disease Progression 10/2015
1	Lymphoma (Lymphomas) 10/2012
1	Infections 10/2012

Drug/Important Bio-Agent (IBA)

7	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2012
7	Proteins (Proteins, Gene)FDA Link 10/2019 - 04/2008
5	Small Interfering RNA (siRNA)IBA 10/2020 - 06/2012
5	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2013
4	LigandsIBA 01/2020 - 08/2009
3	Zoledronic Acid (Zometa)FDA Link 04/2017 - 01/2011
3	Silicon Dioxide (Silica)FDA LinkGeneric 12/2014 - 08/2004
2	Complement C5a (Complement 5a)IBA 01/2022 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2017
2	Biological ProductsIBA 11/2020 - 07/2013
2	CollagenIBA 10/2020 - 02/2012
2	Programmed Cell Death 1 ReceptorIBA 01/2020 - 01/2017
2	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2017
2	Cysteine-Rich Protein 61IBA 01/2019 - 07/2011
2	Cadherins (E-Cadherin)IBA 01/2019 - 08/2004
2	Endothelial Protein C ReceptorIBA 01/2017 - 07/2012
2	Proteoglycans (Proteoglycan)IBA 01/2017 - 06/2012
2	Oncogene Proteins (Oncogene Protein)IBA 01/2013 - 09/2007
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2012 - 01/2011
2	ErbB Receptors (EGF Receptor)IBA 10/2012 - 10/2007
1	Peroxidase (Myeloperoxidase)IBA 01/2022
1	HMGB1 Protein (HMG1)IBA 01/2022
1	HaptoglobinsIBA 01/2022
1	AminopropionitrileIBA 10/2020
1	Gemcitabine FDA Link 07/2020
1	edelfosineIBA 07/2020
1	nasIBA 07/2020
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 01/2020
1	Insulin-Like PeptidesIBA 01/2020
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2020
1	src-Family KinasesIBA 10/2019
1	Dasatinib (BMS 354825)FDA Link 10/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Therapeutic UsesIBA 11/2018
1	Interleukin-33IBA 01/2018
1	LuciferasesIBA 04/2017
1	AntibodiesIBA 01/2017
1	OsteonectinIBA 01/2017
1	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 01/2016
1	Matrix Gla ProteinIBA 01/2016
1	cyclo(Arg-Pro) (CI 4)IBA 12/2015
1	Pharmaceutical PreparationsIBA 10/2015
1	trans-sodium crocetinate (crocetin)IBA 09/2015
1	Dimethylnitrosamine (Nitrosodimethylamine)IBA 12/2014
1	CarcinogensIBA 12/2014
1	SmokeIBA 12/2014
1	Cisplatin (Platino)FDA LinkGeneric 10/2014
1	taxaneIBA 03/2014
1	Monomeric GTP-Binding ProteinsIBA 03/2014
1	CateninsIBA 01/2013
1	ProcollagenIBA 01/2013
1	UbiquitinIBA 10/2012
1	Proto-Oncogene Proteins c-cblIBA 10/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2012
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 10/2012
1	Blocking AntibodiesIBA 07/2012
1	Protein CIBA 07/2012
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2012
1	Methotrexate (Mexate)FDA LinkGeneric 06/2012
1	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2012
1	Cytotoxins (Cytolysins)IBA 06/2012
1	CytokinesIBA 06/2012
1	Endothelin-1 (Endothelin 1)IBA 06/2012
1	Syndecan-2IBA 06/2012
1	Discoidin Domain ReceptorsIBA 02/2012
1	Collagen ReceptorsIBA 02/2012
1	RNA (Ribonucleic Acid)IBA 01/2012

Therapy/Procedure

6	Therapeutics 01/2021 - 01/2017
4	Brachytherapy 01/2021 - 09/2018
4	Drug Therapy (Chemotherapy) 10/2014 - 01/2012
3	Radiotherapy 01/2022 - 01/2018
3	Transplantation 10/2020 - 12/2014
2	Intramuscular Injections 07/2011 - 09/2007
1	Immunotherapy 01/2020
1	Adjuvant Chemotherapy 01/2019
1	Injections 11/2018